How I treat breast implant-associated anaplastic large cell lymphoma.
Neha Mehta-ShahMark W ClemensSteven M HorwitzPublished in: Blood (2018)
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently described form of T-cell non-Hodgkin lymphoma now formally recognized by the World Health Organization classification of lymphoid neoplasms. The disease most often presents with a delayed seroma around the breast implant, almost exclusively with a textured surface, and manifests with breast pain, swelling or asymmetry, capsular contracture, but can also present with a breast mass, and lymph node involvement. The prognosis of BIA-ALCL is favorable compared with many other subtypes of systemic T-cell lymphoma; however, unlike other non-Hodgkin lymphomas, complete surgical excision for localized disease is an important part of the management of these patients. In this paper, we share our recommendations for a multidisciplinary team approach to the diagnosis, workup, and treatment of BIA-ALCL in line with consensus guidelines by the National Comprehensive Cancer Network.
Keyphrases
- lymph node
- single cell
- clinical practice
- diffuse large b cell lymphoma
- end stage renal disease
- quality improvement
- ejection fraction
- newly diagnosed
- chronic pain
- chronic kidney disease
- soft tissue
- cell therapy
- stem cells
- early stage
- deep learning
- pain management
- radiation therapy
- spinal cord
- neuropathic pain
- young adults
- squamous cell
- replacement therapy
- prognostic factors
- mesenchymal stem cells
- lymph node metastasis
- sentinel lymph node